MLYS

Mineralys Therapeutics, Inc.
CAPPED RATING

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Mineralys Therapeutics, Inc. (MLYS) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.0
EV / EBITDA -2.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -39.5%
Price Return 12M -67.1%
Catalyst Signal 0.00
Market Cap $1.4B
TTM Revenue N/A
Price / Sales N/A
ROE -68.5%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C+ (2.6) C (2.3) D+ (1.7) C+ (2.6) C (2.3)
2026-11-06 C+ (2.5) C+ (2.7) C (2.3) D+ (1.6) C+ (2.7) C (2.3)
2026-10-30 C+ (2.5) C+ (2.6) C (2.4) C (2.3) C+ (2.7) C (2.5)
2026-10-23 C+ (2.5) C+ (2.6) C (2.3) C- (2.1) C+ (2.6) C (2.4)
2026-10-16 C+ (2.5) C+ (2.6) C (2.3) C- (2.1) C+ (2.6) C (2.4)
Page 1 of 3